United States

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

4:00pm EDT
Change (% chg)

$3.25 (+3.94%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for BLUE.OQ


bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical... (more)


Beta: 2.23
Market Cap(Mil.): $3,365.61
Shares Outstanding(Mil.): 40.84
Dividend: --
Yield (%): --


  BLUE.OQ Industry Sector
P/E (TTM): -- 57.54 29.95
EPS (TTM): -7.06 -- --
ROI: -26.28 -0.41 13.21
ROE: -30.64 6.21 14.38

BRIEF-Bluebird Bio CEO's 2016 compensation was $4.9 mln

* CEO Nick Leschly's 2016 total compensation was $4.9 million versus $11.2 million in 2015 - sec filing Source text - http://bit.ly/2pmsOYK Further company coverage:

Apr 21 2017

BRIEF-Bluebird Bio announces clinical, biological outcomes

* Announces clinical and biological outcomes for first patient with sickle cell disease treated with gene therapy

Mar 01 2017

BRIEF-Bluebird bio qtrly net loss per share $1.88

* Bluebird Bio reports fourth quarter and full year 2016 financial results and recent operational progress

Feb 22 2017

Medigene eyeing more immunotherapy deals after Bluebird pact

FRANKFURT German biotech firm Medigene said it is drawing more interest from prospective alliance partners for its technology to boost the immune response to cancer after its deal with U.S. peer Bluebird Bio.

Dec 19 2016

Wall Street little changed as bank rally pauses

U.S. stocks ended little changed on Friday after a payrolls report did little to recast expectations for an interest rate hike from the Federal Reserve this month and bank stocks cooled to round out their fourth straight week of gains. | Video

Dec 02 2016

Bluebird, Celgene myeloma treatment impresses in tiny study

Patients who previously were not helped by repeated treatments for multiple myeloma showed strong benefits from a new type of therapy in a small study, and with no worrisome side effects, drugmaker Bluebird Bio Inc said on Wednesday.

Nov 30 2016

BRIEF-Bluebird Bio qtrly loss per share $2.07

* Says HGB-207 and all studies of lentiglobin to incorporate manufacturing process 2 going forward

Nov 02 2016

More From Around the Web

Earnings vs. Estimates